Tissue Regenix Group (LSE:TRX) Total Current Assets : £15.08 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Tissue Regenix Group Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Tissue Regenix Group's total current assets for the quarter that ended in Dec. 2023 was £15.08 Mil.

Tissue Regenix Group Total Current Assets Historical Data

The historical data trend for Tissue Regenix Group's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Regenix Group Total Current Assets Chart

Tissue Regenix Group Annual Data

Trend

Jan14

Jan15

Jan16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

10.14

20.30

16.59

18.09

15.08

Tissue Regenix Group Semi-Annual Data
	Jan14	Jul14	Jan15	Jul15	Jan16	Jul16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Current Assets	Get a 7-Day Free Trial															16.59	16.69	18.09	16.56	15.08

Tissue Regenix Group Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Tissue Regenix Group's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3.674	+	2.908	+	8.183	+	0.316
	=	15.08

Tissue Regenix Group's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3.674	+	2.908	+	8.183	+	0.316
	=	15.08

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Tissue Regenix Group (LSE:TRX) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Tissue Regenix Group's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.674	-	10.972	+	0.75 * 2.391	+	0.5 * 8.183
=	-1.41

Tissue Regenix Group Total Current Assets Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Tissue Regenix Group (LSE:TRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

LSW:Germany

Address

Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY

Website

https://www.tissueregenix.com

Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.